Monogram Biosciences "buy"

06/05/07 - Lazard Capital Markets

NEW YORK, June 5 (newratings.com) - Analyst Jeffrey Frelick of Lazard Capital maintains his "buy" rating on Monogram Biosciences Inc (MGRM). The target price is set to $3.25.

In a research note published yesterday, the analyst mentions that the company has presented data from several studies concerning its e-Tag oncology diagnostic tests at ASCO over the weekend. The analyst considers the early e-Tag data as a positive sign for Monogram Biosciences. Additional oncology catalysts in 2007 could include further e-Tag data, the publication of scientific journals and the announcement of a corporate oncology partner, Lazard Capital adds.